Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: Choosing ART in the Context of Virologic Failure and Resistance

Source: Key Decisions in HIV Care
In this on-demand recording of a live webinar, expert faculty review key considerations when choosing ART for patients with virologic failure and resistance, including how to build an optimized background regimen and the data to support the inclusion of novel therapies into ART regimens.
W. David Hardy, MD
Josep M. Llibre, MD, PhD
Released: December 29, 2021

In this episode from the series “Key Decisions in HIV Care,” W. David Hardy, MD, and Josep M. Llibre, MD, PhD, discuss important considerations for ART use in the context of virologic failure and resistance, including:

  • A discussion of the definitions of the following: highly treatment experienced, complex ART, multidrug-resistant HIV, and limited treatment options
  • The scope of the problem, including data from the CNICS cohort
  • DHHS and EACS guideline recommendations on the management of virologic failure and drug resistance, including recommendations for the use of genotypic and phenotypic genotyping and proviral DNA sequencing
  • Construction of an optimized background regimen with discussion of the OPTIONS, DAWNING, NADIA, and VIKING-3 trials
  • Novel treatment options, including ibalizumab and data from TMB-301/-311, fostemsavir and data from BRIGHTE, and lenacapavir and data from CAPELLA

Information on this Educational Activity

Faculty

W. David Hardy, MD

Scientific and Medical Consultant
Adjunct Clinical Professor of Medicine
Division of Infectious Diseases
Keck School of Medicine of USC
Los Angeles, California

W. David Hardy, MD, has disclosed that he has received consulting fees from Enochian Biosciences, Gilead Sciences, Merck, and ViiV/GlaxoSmithKline.
Josep M. Llibre, MD, PhD

Infectious Disease and “Fight against AIDS and Infectious Diseases Foundation”
Hospital Universitari Germans Trias i Pujol
Badalona
Barcelona, Spain

Josep M. Llibre, MD, PhD, has disclosed that he has served on an advisory board or panel and as a consultant for Gilead Sciences, Janssen, MSD, and ViiV.

Program Medium

This program has been made available online.

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Clinical Care Options (CCO) patient audio: Yvette Raphael provides her perspectives and advice as an individual living with HIV

person default Yvette Raphael Released: June 21, 2022

Clinical Care Options (CCO): South African patient’s perspective on living a full life with her HIV diagnosis, long-term ART, and HIV activism

person default Yvette Raphael Released: June 21, 2022

Audio from Dr Jason Schafer and Clinical Care Options (CCO): Antiretroviral stewardship can address key considerations for ART in the inpatient setting

person default Jason Schafer, PharmD, MPH Released: March 14, 2022

CCO presenta a la Dra. Leticia M. Pérez Saleme explicando los factores principales a tomar en cuenta cuando se toman decisiones basadas en evidencia para optimizar el TAR en pacientes con supresión virológica en México

Leticia M. Pérez Saleme, MD Released: February 17, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings